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ABSTRACT 
 
It is thought that aging in rats and humans is associated with increases in iron 
accumulation and these increases in iron may be associated with increased cellular 
apoptosis.  Here we examine the relationship between cardiac iron levels and 
cardiomyocyte apoptosis in aged F344BN rats which were treated with an oral iron 
chelator (Deferasirox; 100mg/kg body. weight/day) for 6 months.  Compared with 6-
month controls, the levels of cardiac iron, cardiac apoptosis, FLC and DMT-1 were 
higher in 33-month hearts. Deferasirox treatment for six months decreased cardiac iron 
and this was associated with decreases in the number of apoptotic cardiac myocytes.  
Age-associated increases in cardiac apoptosis were coupled with alterations in the 
amount of Bcl-2 and Bax. Deferasirox treatment increased Bcl-2 expression and 
decreased Bad and activated caspase-12 expression. Taken together, these data 
suggest deferasirox may be effective in diminishing age-associated iron accumulation 
and cardiac apoptosis in the aging F344BN rat model. 
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CHAPTER 1 
Introduction 
 
Improved medical care and prevention efforts have contributed to dramatic 
increases in life expectancy in the United States [1]. By the year 2030, the number of 
individuals 65 years and older will reach 70 million in the United States alone while 
persons 85 years and older are expected to be the fastest growing segment of the 
population [1]. Advanced age is a primary risk factor for cardiovascular disease (CVD). 
In the United States, CVD alone accounts for over 40 percent of deaths in those aged 
65 years and above and over 80 percent of all cardiovascular deaths occur in this same 
age group [2]. Clearly, new interventions designed to diminish the incidence or severity 
of CVD would serve to not only diminish morbidity and mortality, but, also the 
burgeoning health care costs associated with treating the aged.   
Aging is defined as a gradual decline of the ability of the organism to defend 
against stress, damage and disease [3]. One of the most well known theories of aging is 
Harman’s oxidative stress theory which postulates that the over production of free 
radicals damage lipids, proteins, and DNA [3]. Reactive oxygen species (ROS) are a 
family of free radicals including superoxide (·O2
-), hydroxyl radical (OH·) and hydrogen 
peroxide (H2O2) that are produced in the heart, and other tissues as a result of cellular 
metabolism [4]. Oxidation of biomolecules due to increased ROS production can alter 
the structure and function of lipids, proteins, and nucleic acids, leading to cellular 
dysfunction and even cell death [4].  
Although not well understood, it is likely that iron contributes to age-associated 
increases in free radical generation. The majority of total body iron is incorporated into 
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haem proteins that include haemoglobin, myoglobin and cytochromes [5]. Additionally, 
the body also contains a pool of non-haem iron that it retains in reserve and for use as a 
cofactor in iron-containing enzymes [5].  As a transition metal, iron possesses the ability 
to fluctuate between multiple oxidation states which gives it the ability to produce 
extremely reactive radical species. For example, in the presence of hydrogen peroxide 
(H2O2), iron catalyses the formation of the highly reactive hydroxyl radical (·OH) via 
Fenton chemistry [6]. Iron accumulation has been shown to occur during aging in a 
variety of tissues, including the liver [7, 8], kidney [7, 8], brain [7, 8], heart [8]. Given the 
ability of iron to participate in the formation of ROS it is likely that age-associated 
increases in cardiac iron may contribute to the increased oxidative stress and cellular 
dysfunction observed in the aging heart.  
Cardiac complications of transfusional siderosis are the most important cause of 
mortality in thalassemic patients as cardiomyocytes are quite vulnerable to the toxic 
effects of excess iron [9]. To diminish the effects of excess iron accumulation in aging, 
iron chelation therapy may be useful. Iron-chelating therapy with deferoxamine (DFO) 
results in a significant improvement in the life expectancy of patients with transfusional 
iron overload [10]. This increased longevity is largely attributed to the prevention of 
heart disease in well-treated patients and, in a few, to the reversal of existing heart 
disease by aggressive intravenous DFO therapy [10]. Unfortunately, compliance with 
the rigorous requirements of daily subcutaneous DFO infusions is still a serious limiting 
factor in treatment success.  
The development of orally effective iron chelators such as Deferasirox (Exjade) 
was motivated at least in part to improve compliance [11]. It is approved for the 
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treatment of chronic iron overload due to blood transfusions in patients 2 years of age 
and older [12]. The primary findings of Phase I and II studies of deferasirox use 
demonstrated dose-related increases in iron excretion and the absence of significant 
acute side effects other than gastrointestinal disturbances that were generally mild or a 
diffuse rash that appeared to be more common at higher doses [12]. Characteristics of 
deferasirox that make it attractive for oral dosing are a half-life of 8 - 16 hours which 
allow a once daily administration [12].  
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Purpose of the Study 
 
The long term goal is to identify if the efficacy of iron chelation is efficacious in 
reducing age-associated increases in cardiac iron. The purpose of this study is to 
determine if deferasirox is capable of diminishing age-associated increases in cardiac 
iron levels.  
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Specific Aims and Hypothesis 
 
It is estimated that by 2053, nearly 25% individuals in the United States will be 
sixty-five years of age or older. Advancing age is associated with the development of 
cardiovascular disease. Although not well understood, recent data has suggested that 
age-related increases in cardiac ROS levels may be associated with cardiovascular 
disease. It is thought that iron accumulation can lead to increased tissue ROS. The 
working hypothesis of this study is that aging in F344BN animals would be associated 
with increases in the cardiac iron content and that deferasirox treatment would be 
efficacious in decreasing tissue iron levels. To test this hypothesis two specific aims are 
proposed.  
 Specific Aim 1:  To determine if aging in F344BN rats associated with increases in  
cardiac iron content. 
Hypothesis 1:  Aging in F344BN rats will be associated with increases in cardiac  
                                 iron content.   
 
Specific Aim 2:  To determine if iron chelation by deferasirox is effective in reducing  
cardiac iron and cardiomyocyte apoptosis. 
Hypothesis 2:  Iron chelation by deferasirox will be effective in reducing cardiac  
                                 iron and cardiomyocyte apoptosis.  
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CHAPTER 2 
 
REVIEW OF LITERATURE 
 
 
This chapter will describe the literature regarding effects of aging on 
cardiovascular structure and function, reactive oxygen species, apoptosis, regulation of 
tissue iron, age-associated cardiac iron accumulation, iron chelation, and Deferasirox. 
 
Effects of aging on cardiovascular structure and function 
Cardiovascular diseases such as atherosclerosis and hypertension that lead to 
heart failure and stroke are the leading cause of mortality in those 65 years and older 
[2]. The clinical manifestations and prognosis of these diseases and resultant heart 
failure worsen with increasing age [13].  
Structural changes in the aging heart include cardiomyocyte  loss, left ventricular 
(LV) hypertrophy, changes of ventricle chamber diameter, and collagen deposition [14-
16]. Functionally speaking, aging in the heart is associated with lengthening of 
contraction / relaxation times and thus a decrease in heart rate [17], decreases in 
fractional shortening, decreased LV end-systolic pressure, and reduced cardiac output 
[17, 18]. Cardiac structure and function are remarkably similar among mammalian 
species, and the use of animal models has been extremely helpful in developing 
treatment strategies for alleviating heart disease in humans [19]. Similar to that seen in 
humans, aging in the Fischer 344 (F344) rat is characterized by myocyte loss and 
reactive hypertrophy of the remaining cardiomyocytes [20]. The mechanisms of myocyte 
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loss appear to be via cardiomyocyte apoptosis and/or necrosis. The causes of tissue 
death are not well understood, but may be related to mitochondrial dysfunction [19]. 
Although F344 rat model are frequently used for aging studies, the Fischer 344/N 
X Brown Norway (F344BN) hybrid exhibits significantly fewer pathological conditions, 
resulting in an increased life expectancy [21]. Recent work has demonstrated that aging 
in the F344BN like humans is associated with alterations in cardiac structure and 
function [19].  Specifically, aging in these animals was characterized by increases in left 
ventricular mass, left ventricular mass/body weight ratio, posterior wall thickness/body 
weight ratio, anterior thickness/body weight ratio, and left ventricular chamber 
diameter/body weight ratio. The mechanisms behind age-related changes in cardiac 
structure and function remain to be determined.  
 
Reactive oxygen species 
Reactive oxygen species (ROS) such as superoxide (·O2
-), hydroxyl radical (OH·) 
and hydrogen peroxide (H2O2) are produced in the heart as a result of cellular 
metabolism.  Under normal physiological conditions, superoxide (·O2
-) is converted to 
the H2O2 by superoxide dismutase (SOD) and eventually the H2O2 is converted in to 
H2O by catalase and glutathione peroxidase[22].  However, with aging, the production 
of ROS in the heart may exceed the buffering capacity and oxidative damage may 
result. Oxidation of biomolecules can alter the lipids, proteins, and nucleic acids 
structure and function which if allowed to proceed unchecked can lead to cellular 
dysfunction and even cell death. 
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Although the exact mechanism of redox disruption is not clear, the free radical 
theory points out increased amounts ·O2
- and deceased amounts of nitric oxide 
formation (NO) or its bioavailability with aging as strong candidates [23]. Whether the 
disruption of redox balance is caused by overproduction of ROS, a deficiency in the 
amount of antioxidants, or a combination of the two, is not clear.  
 
Apoptosis 
Apoptosis is a distinct form of cell death that displays characteristic alterations in 
cell morphology and cell fate [24]. Chromatin condensation and margination that result 
in a “half-moon” or “horseshoe” appearance of the nucleus are typical features of 
apoptotic cell death [24]. In terms of tissue kinetics, apoptosis may be considered a 
mechanism that counter balances the effect of cell proliferation. The deregulation of 
apoptosis has been implicated as a pathogenetic mechanism in a variety of human 
diseases [25]. Indeed, excessive apoptotic cell death may have been found to be 
associated with organ atrophy and failure, as suggested for neurodegenerative 
diseases and viral hepatitis [25]. Apoptotic cell death may also play a critical role in a 
variety of cardiovascular diseases, including myocardial infarction, heart failure, and 
atherosclerosis [25]. Conversely, the inefficient elimination of malignant, autoreactive, 
infected, or redundant cells may lead to the development of neoplasia, autoimmunity, 
viral persistence, and congenital malformations. The factors that regulate age-
associated apoptosis in the heart are not well understood.  
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Iron 
Iron is one of the most common elements in nature and, as a transition metal, is 
essential for electron transport [11]. Iron is required for the functioning of proteins 
involved in oxidative energy production, hemoglobin synthesis, oxygen transport, 
mitochondrial respiration,  and DNA synthesis [11]. Because of its poor solubility, living 
organisms have been compelled to develop efficient mechanisms for iron transport and 
storage[11]. The total amount of human body iron is approximately 3–4 g, two-thirds of 
which is used for red blood cell (RBC) iron while the remainder is stored in ferritin / 
hemosiderin [26]. In the circulation, iron is usually bound to transferrin (Tf), and most of 
the Tf-bound iron is utilized for bone marrow erythropoiesis [26]. 
Iron homeostasis in tissues is regulated by a series of iron-regulatory proteins 
that tightly control cellular iron uptake, storage, export and intracellular iron distribution. 
Dysregulation of these iron-regulatory proteins can lead to intracellular iron overload 
[27]. In thalassemic patients, ineffective erythropoiesis results in a drastic increase in 
plasma iron turnover that is 10–15 times normal [28]. This wasteful production of 
nonviable red blood cells (RBCs) stimulates iron absorption in addition to the iron 
burden contributed by transfusions. Since the capacity of transferrin to carry iron is 
limited, some of this catabolic iron emerges in the plasma in the form of non–transferrin-
bound iron (NTBI) [29, 30]. NTBI is readily available for Fenton type reactions, leading 
to the conversion of reduced iron (Fe2+) to oxidized iron (Fe3+), thus generating 
various free radicals [31, 32]. Under conditions of iron overload, iron in the circulation 
typically exceeds the capacity of iron binding leading to an accumulation of NTBI [33, 
34]. Excess uptake of NTBI into the cells combined with the lack of an effective iron 
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excretory pathway often times leads to the formation of highly reactive oxygen radicals, 
causing peroxidation of membrane lipids and oxidative damage to cellular proteins [31, 
35, 36].  
Iron-overload cardiomyopathy causes 71% of all deaths in patients with 
thalassemia major [37]. Cardiac iron accumulation in iron overload patients has been 
shown to directly correlate with heart diseases such as cardiac arrhythmias, heart 
failure and mortality [38-40]. In situations of chronic iron elevation, excessive free 
radical generation can lead to the depletion of antioxidants and increased cellular 
damage due to the oxidation of lipids, proteins and nucleic acids [32].  
 
Age-associated iron accumulation 
Iron is a catalyst for the formation of reactive oxygen species in biological 
systems. It is well accepted that iron accumulates with senescence in several organs 
[8]. Excess iron can cause serious cellular and tissue damage through its ability to 
formation of highly reactive hydroxyl radicals by electron transfer [41]. Such free 
radicals can damage proteins, lipids and DNA, leading to destruction of organelles, cell 
death and fibrosis. The clinical effects of excess tissue iron include heart disease, 
hepatic dysfunction, and derangement of the endocrine system.  
Although excess iron may be deposited in almost all tissues, most of it is found 
in the reticuloendothelial (RE) cells in the spleen, hepatic Kupffer cells and bone 
marrow, and in parenchymal tissues, such as the myocardium, liver, and endocrine 
organs. In contrast to RE cells where iron accumulation is relatively harmless, 
parenchymal siderosis may result in significant organ damage. Indeed, heart cells are 
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among the most vulnerable to the toxic effects of excess iron, and cardiac complications 
of transfusional siderosis are the most important cause of mortality in thalassemic 
patients [9].  
Fe (III)     Fe (II)
ROS
Apoptosis
 
 
Iron Chelation 
Chelation therapy is the administration of chelating agents to remove heavy 
metals like iron, lead, arsenic, mercury from the body. Iron chelation therapy forms an 
important part of treatment for patients receiving therapy for chronic anemias, b-
thalassemia, sickle cell disease (SCD), and the myelodysplastic syndromes (MDS) [42]  
To diminish these effects of excess iron accumulation in aging, iron chelation 
therapy has been used. Iron-chelating therapy with deferoxamine (DFO) results in a 
significant improvement in the life expectancy of patients with transfusional iron 
overload. This increase in time to death is largely attributed to the prevention of heart 
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disease in well-treated patients and, in a few, to the reversal of existing heart disease by 
aggressive intravenous DFO therapy [10]. In a recent report on thalassemic patients 
treated with DFO, survival at 40 years was 83%, and in compliant patients born after 
1975, survival at 25 years was 100% [43]. This improvement in survival was reflected in 
an inverse, mirror like decrease in cardiac mortality supporting the assumption that 
prevention of cardiac mortality is the most important beneficial effect of DFO therapy 
[44]. The strongest direct evidence supporting the beneficial effect of DFO on 
hemosiderotic heart disease is the reversal of established myocardiopathy in some far 
advanced cases [44]. Previously, the course of established myocardial disease in 
transfusional hemosiderosis was considered fatal [44] however more recent data has 
suggest that patients may still be salvaged by intensified chelation treatment [44]. 
Prevention of cardiac mortality is the most important beneficial effect of iron chelation 
therapy. Unfortunately, compliance is poor given the requirement of daily subcutaneous 
deferoxamine (DFO) infusions. The development of orally effective iron chelators such 
as deferasirox (ICL670) has been driven as a means to improve compliance [11]. 
 
Deferasirox 
Deferasirox (ICL670, Exjade®) is the first orally active iron chelator available for 
routine use in the United States. It is approved for the treatment of chronic iron overload 
due to blood transfusions in patients 2 years of age and older [12]. As a tridentate 
chelator, two molecules of deferasirox bind one molecule of iron. The half-life of 8-16 
hours allows once daily administration [12]. Iron excretion is mainly in the feces [12]. 
The primary findings in Phase I and II studies of deferasirox were dose-related 
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increases in iron excretion and the absence of significant acute side effects other than 
gastrointestinal disturbances that were generally mild and a diffuse rash that appeared 
to be more common at higher doses. Evaluation of patient satisfaction with therapy has 
demonstrated superiority of deferasirox over DFO which is hoped to translate into 
improved compliance [42]. Whether deferasirox is capable of diminishing cardiac iron 
levels is not well understood. 
Binding of deferasirox with iron  
 
                                                                  (journals.prous.com/.../images/struc01.gif) 
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Summary 
Cardiovascular disease is leading cause of mortality in aged people. Aging is 
associated with changes in cardiovascular structure and impairments in function. 
Reactive oxygen species (ROS) increase with age and it is thought that increased 
cardiac ROS can lead to the oxidation of biomolecules and increased cardiac apoptosis. 
Iron has been found to accumulate in the heart with age and it has been postulated that 
this increase in cardiac iron may lead to increased ROS. The effects of iron chelation on 
age-associated increases in cardiac iron levels are unknown. Exjade is a new class of 
iron chelators that can be taken orally. To our knowledge, it is not known if deferasirox 
is capable of attenuating age-associated increases in cardiac iron.  
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CHAPTER 3 
 
Deferasirox decreases age-associated iron accumulation in the aging F344BN rat 
heart 
 
 
 
 
Note: Chapter 3 has been formatted for publication purposes. 
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Abstract 
It is thought that aging in rats and humans is associated with increases in iron 
accumulation and that these increases in tissue iron may be associated with increased 
cellular apoptosis.  Here we examine the relationship between cardiac iron levels and 
cardiomyocyte apoptosis in aged F344BN rats that had been treated with an oral iron 
chelator (Deferasirox; 100 mg / kg body weight / day) daily for 6 months.  Compared 
with tissues obtained from 6-month control animals, the amount of cardiac iron (+72%), 
ferritin light chain (+59%), divalent metal transporter-1 (+56%) and the level of cardiac 
apoptosis (+89%) were higher in 33-month aged hearts (P<0.05). Deferasirox treatment 
for six months decreased cardiac iron levels by 37% (P<0.05) and this was associated 
with decreases in the number of apoptotic cardiac myocytes.  Age-associated increases 
in cardiac apoptosis were coupled with alterations in the amount of Bcl-2 and Bax. 
Deferasirox treatment increased Bcl-2 expression 17% (P<0.05) and decreased Bad, a 
proapoptotic protein and activated caspase-12 expression by 35% and 48%, 
respectively (P< 0.05). Taken together, these data suggest deferasirox may be effective 
in diminishing age-associated iron accumulation and cardiac apoptosis in the aging 
F344BN rat model.  
 
Wc =189 
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Introduction 
Advancing age is associated with an increased risk of cardiovascular diseases  
[45].  Although not well understood, it is thought that the profound impact of age on the 
risk of the occurrence, severity and prognosis of cardiovascular disease is due, in part, 
to age-associated changes in cardiovascular structure and/or function [46]. Although 
there is no clear consensus on the mechanism(s) that may be responsible for these 
age-related alterations, increases in reactive oxygen species (ROS) and oxidative 
stress have been posited as being involved [47]. The “free radical theory of aging” 
proposes that aging allows for gradual damage to biomolecules via free radical 
reactions [48]. The basis for these changes is still not fully understood, but it has been 
reported that iron causes oxidative stress in the body while other studies have 
demonstrated that aging in animals (rats) and humans is associated with increases in 
iron accumulation [7, 49-51].   
Cardiomyopathy from excess cardiac iron is the major cause of death in 
thalassemia patients as iron accumulation in the heart has been linked to cardiac 
hypertrophy, dilatation, and cardiac myocyte death [48, 52].  The survival of patients 
with beta thalassemia and sickle cell anemia is determined by the magnitude of cardiac 
iron-loading [52]. Iron chelation has been found to exert a beneficial cardiovascular 
effect in most situations of iron overload, whether genetically determined (such as in 
hemochromatosis) or caused by excessive transfusions. In addition, iron chelation or 
deprivation has also been shown to act as a potent anti-oxidant in a variety of animal 
models of human diseases, preventing oxidative stress to tissues and organs [53, 54].  
Despite this evidence, the possibilities of pharmacologically targeting iron to improve  
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“successful aging” or to reduce age-associated alterations in cardiovascular structure or 
function have remained essentially unexplored.  
We and others have demonstrated that aging in the Fischer 344BN rat model is 
characterized by changes in cardiovascular morphology and function along with 
increases in cardiac ROS [19, 55-57]. Whether these changes in the cardiovascular 
system were associated with age-associated iron accumulation or if iron chelation may 
be beneficial in diminishing these age-associated changes has not been investigated. 
The purpose of this study was to examine if iron chelation was capable of reducing iron 
in aging F344BN rats and to determine if changes in tissue iron levels, if present, were 
associated with alterations in cardiac apoptosis and the expression of key regulators of 
intracellular iron. We hypothesized that aging in F344BN animals would be associated 
with increases in the cardiac iron content, cardiomyocyte apoptosis, and corresponding 
changes is key intracellular iron regulators and that iron chelation would be effective in 
reducing the magnitude of these variables. To test this hypothesis, we examined the 
relationship between cardiac iron levels, cardiomyocyte apoptosis, and key intracellular 
iron regulators in aged (33 month) control and treated F344BN rats that had been daily 
treated with an oral iron chelator (Exjade; 100 mg / kg body weight / day) daily for 6 
months. Taken together, our findings suggest that aging in the F344BN heart is 
associated with increases in cardiac iron and cardiac apoptosis and that deferasirox is 
effective in diminishing age-associated increases in each of these variables.  
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Materials and Methods 
 
Animals  
Male Fischer F344BN rats (National Institute on Aging, Bethesda, MD), aged 6 
and 27 months, and were housed in an AAALAC approved vivarium. Housing conditions 
consisted of a 12:12 h light / dark cycle and temperature was maintained at 22 ± 2°C. 
Water and food (LabDiet 5001, PMI Nutrition International, LLC, Brentwood, MO) were 
provided ad libitum. Animals were allowed to acclimate to the housing facilities for at 
least two weeks before experimentation began. During this time the animals were 
carefully observed and weighed weekly. None of the animals exhibited signs of failure to 
thrive, such as precipitous weight loss, disinterest in the environment, or unexpected 
gait alterations. Animal care and procedures were conducted in accordance with the 
Animal Use Review Board of Marshall University using the criteria outlined by the 
American Association of Laboratory Animal Care (AALAC) as proclaimed in the Animal 
Welfare Act (PL89-544, PL91-979, and PL94-279). 
 
Materials 
Antibodies against glyceraldehyde 3-phosphate dehydrogenase (GAPDH) 
(#2118), Bcl-2 (#2870), Bad (#9292), Bax (#2772), Caspase-12 (#2202), biotinylated 
protein ladder, mouse and rabbit IgG antibodies were purchased from Cell Signaling 
Technology (Beverly, MA). Ferritin light chain (FERL14-A), and divalent metal ion 
transporter (DMT1) (NRAMP21-A) were procured from Alpha Diagnostic International 
(San Antonio, TX). Transferrin receptor 1 (TfR1) was from AbD Serotec (Raleigh, NC). 
Precast 10% SDS-PAGE gels were purchased from Cambrex Biosciences (Baltimore, 
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MD), and enhanced chemiluminescence (ECL) western blot detection reagent was 
acquired from Amersham Biosciences (Piscataway, NJ).  Restore western blot stripping 
buffer was obtained from Pierce (Rockford, IL) and 3T3 cell lysates were from Santa 
Cruz Biotechnology (Santa Cruz, CA).  All other chemicals were purchased from Sigma 
(St. Louis, MO).  
 
Iron chelation  
To avoid the stress of chronic, repeated gavage feeding, deferasirox was 
homogenously mixed in plain peanut butter for oral feeding via a 1-mL syringe (n=6 ea 
group). Deferasirox was provided by Novartis Pharma, AG (Basel, Switzerland) and was 
given at a single daily dosage of 100 mg/kg for six months as outlined previously [58].  
 
Laboratory evaluation of iron-induced cardiac, liver, and renal damage   
 Appropriate whole blood and serum samples were obtained from rats at 
necropsy and evaluated for cardiac toxicity (Alanine aminotransferase (ALT)), liver 
toxicity (Aspartate aminotransferase (AST), Alanine aminotransferase  (ALT), Alkaline 
phosphatase (ALP), bilirubin), renal toxicity (Blood urea nitrogen (BUN), creatinine) 
albumin (ALB),Calcium  (Ca+2),  Creatinine (CRE), Amylase (AMY), Globulin (GLOB),  
Potassium  (K+), Sodium (Na+), Phosphorous (PHOS), Total bilirubin (TBIL), Total 
protein (TP) utilizing a VetScan® Classic (Abaxis, Union City, CA, USA) with a 
Comprehensive Diagnostic Profile Disk. 
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Heart collection 
Rats were anesthetized with a ketamine-xylazine (4:1) cocktail (50 mg/kg i.p.) 
and supplemented as necessary for reflexive response.  After midline laparotomy, the 
heart was removed and placed in Krebs-Ringer bicarbonate buffer (KRB) containing: 
118 mM NaCl, 4.7 mM KCl, 2.5 mM CaCl2, 1.2 mM KH2PO4, 1.2 mM MgSO4, 24.2 mM 
NaHCO3, and 10 mM α-D-glucose (pH 7.4) equilibrated with 5% CO2/ 95% O2 and 
maintained at 37°C.  Isolated hearts were quickly massaged to remove any blood from 
the ventricles, cleaned of connective tissue, weighed, and immediately snap frozen in 
liquid nitrogen. 
 
Determination of organ metal levels  
Portions of the hearts, were removed, weighed, and sent for quantitative iron 
determination (University of Tampa, Tampa, Fl) by inductively coupled plasma-atomic 
emission spectroscopy (ICP-AES), (n=6) [59].  Briefly, digestions were performed using 
commercially available trace metal grade HNO3 (Thermo Fisher Scientific).  Dilutions 
were made with 2% (vol.) HNO3 (trace metal grade) prepared with deionized water.  All 
digestion tubes, volumetric pipettes, and volumetric glassware were soaked for 24 
hours in 2% (vol.) HNO3 (trace metal grade), rinsed four times with deionized water, and 
air dried prior to use.  Approximately 300 mg (wet weight) of sample was weighed into a 
glass digestion tube and 6.0 ml of concentrated trace metal grade HNO3 added. A 1000 
mg/L Yttrium solution in 2% HNO3 (PerkinElmer), used as an internal standard (final 
concentration 1.67 mg/L), was added to each tube.  Samples were heated at 37oC for 1 
hour and then at 110oC for 2 hours.  After digestion, 5.0 ml of the clear solution was 
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transferred to a 50 ml volumetric flask and brought to volume with 2% (vol) HNO3 (trace 
metal grade).  Solutions were filtered through a 0.22 μm syringe driven filter unit 
(Millipore) and analyzed by Inductively Coupled Plasma-Atomic Emission Spectroscopy 
(ICP-AES). A 1.67 mg/L iron solution was used as a control for the digestion procedure.  
Analyses were performed on a Perkin Elmer ICP-AES (Optima 2100 DV) using a 0 to 1 
mg/L, 0 to 10 mg/L, or 0 to 100 mg/L (for iron only) standard curve, depending upon the 
metal concentration. Calibration and control solutions for the 0 to 1 mg/L and 0 to 10 
mg/L standard curves were prepared from a multi-element standard (ICP Multi-element 
Solution 2, Spex Chemicals, 10 mg/L).  Calibration and control solutions for the 0 to 100 
mg/L standard curve were prepared from a 1000 mg/L iron standard solution 
(PerkinElmer, Waltham, MA).   All calibrators and controls contained an internal Yttrium 
standard. The measurements for iron (238.204 nm), copper (327.393 nm), zinc 
(206.200 nm), magnesium (280.271 nm), and manganese (257.610 nm) were 
conducted in the axial mode, while calcium (393.366 nm) was measured in the radial 
mode.  Sample concentrations were determined from standard curves generated by 
linear regression analysis.  The minimal detectable concentration for each metal was 
determined using the mean plus the three-fold standard deviation obtained from 10 
blank digestions. 
 
TUNEL staining  
DNA fragmentation was determined by TdT-mediated dUTP nick end labeling 
(TUNEL) according to the manufacturer’s recommendations.  TUNEL staining was 
performed on tissue sections (8 μm) obtained from 6- (n = 6), 33 control- (n = 6), and 33 
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treated- (n = 6) month hearts, which were fixed with 4% paraformaldehyde, washed with 
PBS (pH 7.4), and then permeabilized with 0.1% sodium citrate and 0.1% Triton X.  
Cross-sections from each heart were treated with DNase I to induce DNA fragmentation 
as a positive control.  Three randomly selected regions from each cross section were 
visualized by epifluorescence using an Olympus fluorescence microscope (Melville, NY) 
fitted with a 20X objective.  Images were recorded digitally using a CCD camera 
(Olympus, Melville, NY), and the samples were analyzed by counting positively stained 
nuclei. 
 
Immunoblot analysis 
Hearts were pulverized in liquid nitrogen using a mortar and pestle until a fine 
powder was obtained.  After washing with ice cold PBS, samples were lysed on ice for 
15 min in T-PER (2 ml/1g tissue weight) and centrifuged for 10 min at 12000 x g.   The 
supernatant was collected and the protein concentrations of homogenates were 
determined in triplicate via the Bradford method (Pierce) using bovine serum albumin as 
a standard.  Samples were solubilized at a concentration of 3mg/ml in SDS-loading 
buffer and boiled for 5 minutes. forty µg of protein from each sample was separated on 
10% SDS-PAGE gels and then transferred onto Hybond nitrocellulose membranes 
using standard conditions [60]. 
To verify transfer of proteins and equal loading of lanes the membranes were 
stained with Ponceau S.  For immunodetection, membranes were blocked in 5% milk 
Tris buffered saline with 0.5% tween-20 (TBST) for 1 hr at room temperature and then 
incubated with the appropriate primary antibody overnight.  After washing in TBST, the 
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membranes were exposed to horseradish peroxidase-(HRP)-labeled IgG secondary 
antibody for 1 hr and protein bands were visualized with ECL (Amersham Biosciences).  
Exposure time was adjusted to keep the integrated optical densities (IODs) within a 
linear and nonsaturated range.  Band signal intensity was quantified by densitometry 
using a flatbed scanner (Epson Perfection 3200 PHOTO) and Imaging software 
(AlphaEaseFC).  Equal protein loading between lanes and gels was determined by 
normalizing to the amount of Ponceau S stained protein transferred to the membranes 
or by GAPDH intensity. Molecular weight markers (Cell Signaling) were used as 
molecular mass standards and NIH 3T3 cell lysates were included as positive controls. 
At least three SDS-PAGE gels were run for each experimental set to evaluate changes 
in dependent variable tissue content and basal phosphorylation where applicable.  
Immunoblots were stripped with Restore western blot stripping buffer as described by 
the manufacturer to obtain direct comparisons between expression and phosphorylation 
levels of different signaling molecules.  After verifying the absence of residual HRP 
activity by reacting with the membrane with the ECL reagent, membranes were washed 
and reprobed.   
 
Data analysis 
Results are presented as means ± SEM. Data were analyzed by using the 
SigmaStat v.3.5 statistical program. Oneway analysis of variance (ANOVA) was 
performed for overall comparisons while the Student-Newman-Keuls post hoc test used 
to determine differences between groups.  Regression analysis of the dependent 
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variables was performed across age groups using values from six individual hearts from 
each group.  Values of P < 0.05 were considered to be statistically significant. 
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Results 
Total body and heart weights were obtained and compared (Table 1).  All 
animals tolerated the chelation without any apparent ill effects.  The body weights of the 
treatment and age matched control were similar to 6-month controls.  Compared to 6-
month animals, aging increased the heart to body weight ratio by 46% (P < 0.05), (Table 
1).  Deferasirox treatment did not alter the heart to body weight ratio.  
 
Deferasirox decreases age-associated increases in cardiac iron   
Compared to tissues obtained from 6-month control animals, the iron content of 
the aged heart was 72% higher (P<0.05) (Fig.1).  Deferasirox treatment for six months 
decreased cardiac iron levels by 37% (P<0.05).  Neither aging nor deferasirox treatment 
altered cardiac copper, zinc or magnesium levels (Table 1).  Tissue levels of calcium 
were 53% higher in the 33-month control hearts (P<0.05) compared to 6-month control 
hearts.  
 
Aging increases the expression of iron regulatory proteins 
Compared to 6-month control animals, the amount of ferritin light chain was 57% 
and 83% higher in 33-month control and 33-month treated animals, respectively 
(P<0.05) (Table 2).  Similarly, DMT-1 levels were 57% and 78% higher in 33-month 
control and 33-month treated animals, respectively (P<0.05) (Fig. 2).  IRP-1 and TfR-1 
levels were unchanged with both aging and treatment.  
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Age-associated changes in indices of liver and kidney function 
Compared to 6-month control animals, ALP, BUN and PHOS levels in venous 
blood were 7%, 24%, and 35% lower, respectively (P<0.05) (Table 3). Globulin and Na+ 
levels  were 33% and 5% higher in aged animals compared to that observed in 6-month 
control animals (P<0.05) and unaltered by deferasirox treatment (Table 3).  Deferasirox 
treatment for 6-months decreased the ALP levels by 26% compared to age matched 
control animals (P<0.05) (Table 3). Changes in the other blood parameters were not 
significantly different with age or treatment.   
 
Deferasirox treatment decreases indices of age-associated cardiomyocyte 
apoptosis 
Compared to 6-month animals, the number of TUNEL positive cells was 
approximately 15.7 times  higher in 33-month control animals and with deferasirox 
treatment  it was demonstrated that the number of TUNEL positive cells was decreased 
by 67.1% compared to age matched controls (P< 0.05) (Fig. 3).   The ratio of Bax and 
Bcl-2 expression is thought to be  key regulator of apoptosis [61]. Aging was associated 
with higher levels of Bax (P< 0.05) while Bcl-2 levels were unchanged (Fig. 4, Table 2).  
Similarly, the expression of Bad was 28% higher (P< 0.05) in 33-month old animals (Fig. 
5).  Compared to age-matched controls, deferasirox decreased Bad and activated 
caspase-12 expression by 49% and 18%, respectively (P< 0.05) (Figs. 5, 6).   
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Discussion 
Recent data has suggested age-related increases in iron may lead to increased 
levels of redox-active iron and iron-mediated oxidative stress [62].  In the aging heart, 
increases in oxidative stress have been posited to play a role in dysrhythmia, cardiac 
injury, and cardiomyocyte death [63].  In comparison to other rat strains, the F344BN 
appears to exhibit diminished age-related pathophysiology leading some to hypothesize 
that this model may be more appropriate than others for investigation of the effects of 
aging on physiological function [21, 64, 65].  We and others have recently demonstrated 
that aging in the F344BN is associated with increases in heart mass, left ventricular 
hypertrophy, increased incidence of cardiac arrhythmias, decreased ventricular 
compliance and impairment in systolic and diastolic function [19, 57] as well as 
increased expression of oxidative-nitrosative stress markers in the myocardium [55].  As 
in humans, the induction mechanisms that underlie these degenerative changes are not 
fully understood.  Here we examine if aging in the F344BN rat is associated with 
increased tissue iron levels, if iron chelation can influence tissue iron in the aging 
F344BN, and whether a relationship exists between cardiac iron levels and 
cardiomyocyte death.  
It is difficult to gauge iron status, particularly iron stores, based on traditional 
laboratory tests which are often confounded by the presence of infection, inflammation 
or disease in older adults [66, 67].  Several investigations have, therefore, focused on 
examination of tissue iron stores with aging in various animal models.  Consistent with 
previous data obtained in the Sprague Dawley rat and humans [68, 69], here we 
demonstrate that aging in the F344BN rat was associated with increased levels of 
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cardiac and liver iron (Fig. 1).  Iron is essential for critical life functions, including oxygen 
transport, energy metabolism and cell proliferation. Given its biological importance, as 
well as its toxicity, iron levels are typically precisely regulated under normal physiology 
conditions via several intricate feedback mechanisms involving transporters, iron-
binding proteins and receptors [51, 70].  Why aging might be associated with increased 
cardiac iron levels has not been fully elucidated. 
One major finding of the present study is that deferasirox appears to be 
efficacious for the removal of cardiac iron in the aged rat (Fig. 1).  In addition, these 
data also suggest that deferasirox is quite specific as we failed to find any impact of 
chronic deferasirox treatment on tissue calcium, copper, zinc or magnesium levels 
(Table 2).  To our knowledge these findings have not been demonstrated before in this 
animal model. Consistent with previous data collected in aging Sprague Dawley rats 
[71], we did not find any difference in tissue iron levels in aging kidney (data not shown).  
Why some tissues appear to accumulate iron with aging while others do not is not well 
understood but is likely related to differences in iron transport mechanisms between 
different cell and tissue types [70].   
To examine the possibility that the increased cardiac iron we observed is 
associated with alterations in the expression of iron regulatory proteins we examined 
the effects of aging on cardiac ferritin, divalent metal transporter-1 (DMT-1), transferrin 
receptor-1 (TfR-1) and iron regulatory protein-1 (IRP-1) levels.  Ferritin is a 24-subunit 
protein comprised of heavy and light chains that has been shown to function as the 
main intracellular storage protein for iron [72].  Conversely, DMT-1  and TfR-1 are iron 
transport proteins that are thought to be involved in regulating the uptake of non-haem 
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iron from the circulation [73] while IRP-1 has been demonstrated to regulate the 
expression of critical iron regulation proteins at the post-translational level [74].  Similar 
to recent work examining the regulation of iron regulatory proteins in the skeletal 
muscles of aged F344 rats [68], we found that aging was associated with a significant 
increase in the amount of cardiac ferritin light chains (Fig. 2).  Consistent with our 
findings of age-associated cardiac iron accumulation, we also found that the aged 
F344BN hearts also exhibited increased levels of DMT-1.  Whether these increases in 
the amount of DMT-1 and ferritin are fully responsible for the age-associated increases 
in cardiac iron we observe or whether these factors act in concert with other 
mechanisms is currently unknown. Although unlikely to play a major role, some have 
proposed that oxidant stress itself may be involved in the accumulation of iron levels as 
superoxide radicals have been observed to liberate iron from ferritin [75].  It is currently 
unclear if this process is occurring in the aging F344BN heart and what degree this 
process, if present, may play in increasing tissue iron levels will require further 
investigation.  
Given that the length of deferasirox treatment (6 months) used in this study is 
likely quite similar to several decades of human life we examined several different blood 
parameters in an attempt to ascertain if chronic deferasirox administration adversely 
affected animal health [76].  With the exception of alkaline phosphatase (ALP) levels, 
which were decreased but within the normal range, no significant differences in any of 
the parameters measured were observed in treated compared to age-matched control 
animals (Table 2).  Taken together, these data suggest that long term deferasirox 
treatment is not associated with poor animal health in the F344BN aging rat model.  
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Recent evidence has suggested that apoptosis may play a considerable role in 
mediating age-associated cardiac dysfunction in both rats and humans [77].  Indeed, 
increased myocyte apoptosis is directly related to dysfunction and pathology in the heart 
exhibited with aging, cardiovascular disease, cardiomyopathy and heart failure.  
Intriguing evidence also indicates that apoptotic signaling and caspase activation 
increases protein degradation and impairs contractile function, independent of cell loss 
[78].  Here we observed an increase in the number of cells exhibiting morphological 
changes consistent programmed cell death or apoptosis. Specifically, with aging we 
demonstrate an increase in the number of nuclei staining positive for DNA strand 
breakage as determined by the TUNEL assay (Fig. 2).  This finding is in agreement with 
the recent findings of Phaneuf and Leeuwenburgh who demonstrated an age-
associated increase in the number of apoptotic nuclei in the aging rat heart [79].  The 
degree to which apoptosis contributes to myocyte loss and cardiac dysfunction in the 
aging F344BN rat is not well understood.  Nonetheless, the findings of the present study 
are consistent with previous reports by our laboratory and others demonstrating that 
cardiac function in the aging F344BN are impaired with aging [19, 57, 80].  In addition 
these data also suggest that age related increases in cardiac iron may play a role in 
cardiac apoptosis.  Importantly, we also demonstrate that deferasirox treatment is 
associated with a decrease in the number of cardiomyocytes exhibiting a TUNEL 
positive signal.  Whether the decreases in TUNEL positive cells we observe with 
deferasirox treatment are associated with improvements in cardiac performance or are 
directly linked to deferasirox induced changes in tissue iron levels is not known.  Future 
research aimed at investigating these research questions will no doubt be useful in 
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addressing the potential for deferasirox for treating age-related cardiovascular 
dysfunction.  
The mechanism(s) regulating cardiac apoptosis are not fully understood.  
Apoptotic signaling induces apoptosis primarily through three types of complex 
pathways. They include 1) cytokine/Fas receptor-driven pathway, 2) mitochondrial-
driven pathway, and 3) endoplasmic reticulum/Ca2+-driven pathway [81].  Among them, 
the mitochondrial-mediated pathway, including the Bcl-2 family is the best characterized 
and believed to be critical in regulating apoptosis with aging [77].  Indeed, progressive 
impairment of mitochondrial function is a hallmark of aging and has been linked with 
apoptosis.  Although this pathway includes multiple proteins, the regulation and 
interaction of the anti-apoptotic Bcl-2 and the pro-apoptotic Bax appear to play key 
roles.  Current research suggests that Bcl-2 forms a heterodimer with Bax that prevents 
Bax homodimerization, its insertion into the mitochondrial membrane, and the release of 
cytochrome-c [82].  It is thought that the ratio of Bax to Bcl-2 plays an important role in 
regulating the release of cytochrome-c from the mitochondria into the cytosol with the 
release of cytochrome-c and cell death favored as the balance shifts toward Bax [83]. 
Consistent with the TUNEL findings, we observed a large increase in the amount of Bax 
in the aging F344BN heart (Fig. 4).  To further confirm the possibility that that Bcl-2 / 
Bax might be involved in the cardiac apoptosis we also examined the effects of aging on 
Bad expression.  Bad is a pro-apoptotic member of the Bcl-2 family that can displace 
Bax binding from Bcl-2 and Bcl-XL, resulting in cell death [84].  Similar to Bax, we 
observed that Bad levels increased with aging (Fig. 5).  Importantly, we also 
demonstrate that deferasirox treatment is associated with a significant increase in the 
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anti-apoptotic Bcl-2 and a decrease in pro-apoptotic Bad.  Taken together, these data 
suggest that the mitochondrial-mediated processes may play a role in age-associated 
cardiomyocyte death and that deferasirox may decrease age-associated cardiomyocyte 
apoptosis, possibly be altering the expression of Bcl-2 and Bad.  
In an effort to examine other mechanisms of apoptosis we also examined the 
regulation of caspase-12 (Fig. 6).  Caspase-12 is one of the key effectors of the 
endoplasmic reticulum/Ca2+-driven pathway that is thought to be activated in response 
to calcium dyshomeostasis or endoplasmic reticulum (ER) stress [85].  Here, we failed 
to observe any age-associated changes in the amount of cleaved (activated) caspase-
12 suggesting perhaps that ER stress does not play a major role in regulating cardiac 
apoptosis in the aging F344BN heart (Fig. 6).  Nonetheless, it is of interest to note that 
we found that deferasirox treatment appeared to decrease the amount of caspase-12 
activation.  Whether this treatment associated change in caspase-12 is also associated 
with the decrease in the number of TUNEL positive cells we observed with deferasirox 
treatment is unknown.  
Taken together, the data of the present study suggest that deferasirox treatment 
can effectively reduce age-associated increases in cardiac iron and cardiomyocyte 
apoptosis.  Future studies examining other animal models and other indices of age-
associated dysfunction will no doubt be useful in determining the usefulness of 
deferasirox as an intervention. 
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CHAPTER 4 
 
Conclusions 
 
1. Aging increases cardiac iron content in F344BN rats.   
2. Increased cardiac iron content with age alters the expression of proteins 
associated with apoptotic signaling. 
3. Increased cardiac iron content with age alters the expression of proteins thought 
to be involved in regulating tissue iron levels.  
4. Iron chelation by deferasirox is effective in reducing cardiac iron content in 
F344BN rats. 
5. Iron chelation by deferasirox is effective in reducing cardiomyocyte apoptosis.  
6. Iron chelation by deferasirox is effective in reducing in corresponding changes in 
key intracellular iron regulators. 
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Future Directions 
 
In this present study we examined the effects of aging on cardiac iron 
accumulation and whether or not deferasirox was efficacious in reducing cardiac iron 
content. To continue this study, future investigations could examine the effects of aging 
and deferasirox treatment on iron accumulation in other vital organs such as the liver, 
kidney and skeletal muscles.  
Other work could explore the possibility of including other chelators with 
deferasirox to determine if combination therapy would lead to synergistic or additive 
effects.  
Finally, in the present study we used only the F344BN rat model. Whether 
deferasirox would have similar effects in other aging models or humans is currently 
unclear. Future studies addressing this possibility would no doubt be useful in furthering 
our understanding of the effects of age and chelation on tissue iron levels.  
  
 
 
 
 
 
 
 
 
44 
 
REFERENCES 
 
1. American College of Sports Medicine Position Stand. Exercise and physical  
activity for older adults. Med Sci Sports Exerc 1998; 30: 992-1008. 
2. Lakatta EG. Age-associated cardiovascular changes in health: impact on 
cardiovascular disease in older persons. Heart Fail Rev 2002; 7: 29-49. 
3. Frisard M, Ravussin E. Energy metabolism and oxidative stress: impact on the 
metabolic syndrome and the aging process. Endocrine 2006; 29: 27-32. 
4. Davies KJ. Oxidative stress: the paradox of aerobic life. Biochem Soc Symp 
1995; 61: 1-31. 
5. Finch CA, Huebers H. Perspectives in iron metabolism. N Engl J Med 1982; 306: 
1520-1528. 
6. Gutteridge JM, Halliwell B. Iron toxicity and oxygen radicals. Baillieres Clin 
Haematol 1989; 2: 195-256. 
7. Cook CI, Yu BP. Iron accumulation in aging: modulation by dietary restriction. 
Mech Ageing Dev 1998; 102: 1-13. 
8. Sohal RS, Wennberg-Kirch E, Jaiswal K, Kwong LK, Forster MJ. Effect of age 
and caloric restriction on bleomycin-chelatable and nonheme iron in different tissues of 
C57BL/6 mice. Free Radic Biol Med 1999; 27: 287-293. 
9. Borgna-Pignatti C, Rugolotto S, De Stefano P, Piga A, Di Gregorio F, Gamberini 
MR, Sabato V, Melevendi C, Cappellini MD, Verlato G. Survival and disease 
complications in thalassemia major. Ann N Y Acad Sci 1998; 850: 227-231. 
10. Gabutti V, Piga A. Results of long-term iron-chelating therapy. Acta Haematol 
1996; 95: 26-36. 
11. Hershko C, Link G, Konijn AM, Cabantchik ZI. Objectives and mechanism of iron 
chelation therapy. Ann N Y Acad Sci 2005; 1054: 124-135. 
12. Cohen AR. New advances in iron chelation therapy. Hematology Am Soc 
Hematol Educ Program 2006: 42-47. 
13. McKee PA, Castelli WP, McNamara PM, Kannel WB. The natural history of 
congestive heart failure: the Framingham study. N Engl J Med 1971; 285: 1441-1446. 
45 
 
14. Anversa P, Palackal T, Sonnenblick EH, Olivetti G, Meggs LG, Capasso JM. 
Myocyte cell loss and myocyte cellular hyperplasia in the hypertrophied aging rat heart. 
Circ Res 1990; 67: 871-885. 
15. Capasso JM, Fitzpatrick D, Anversa P. Cellular mechanisms of ventricular failure: 
myocyte kinetics and geometry with age. Am J Physiol 1992; 262: H1770-1781. 
16. Capasso JM, Palackal T, Olivetti G, Anversa P. Severe myocardial dysfunction 
induced by ventricular remodeling in aging rat hearts. Am J Physiol 1990; 259: H1086-
1096. 
17. Chang KC, Peng YI, Dai SH, Tseng YZ. Age-related changes in pumping 
mechanical behavior of rat ventricle in terms of systolic elastance and resistance. J 
Gerontol A Biol Sci Med Sci 2000; 55: B440-447. 
18. Pacher P, Mabley JG, Liaudet L, Evgenov OV, Marton A, Hasko G, Kollai M, 
Szabo C. Left ventricular pressure-volume relationship in a rat model of advanced 
aging-associated heart failure. Am J Physiol Heart Circ Physiol 2004; 287: H2132-2137. 
19. Hacker TA, McKiernan SH, Douglas PS, Wanagat J, Aiken JM. Age-related 
changes in cardiac structure and function in Fischer 344 x Brown Norway hybrid rats. 
Am J Physiol Heart Circ Physiol 2006; 290: H304-311. 
20. Anversa P, Hiler B, Ricci R, Guideri G, Olivetti G. Myocyte cell loss and myocyte 
hypertrophy in the aging rat heart. J Am Coll Cardiol 1986; 8: 1441-1448. 
21. Lipman RD, Chrisp CE, Hazzard DG, Bronson RT. Pathologic characterization of 
brown Norway, brown Norway x Fischer 344, and Fischer 344 x brown Norway rats with 
relation to age. J Gerontol A Biol Sci Med Sci 1996; 51: B54-59. 
22. Turrens JF, Boveris A. Generation of superoxide anion by the NADH 
dehydrogenase of bovine heart mitochondria. Biochem J 1980; 191: 421-427. 
23. Afanas'ev IB. Free radical mechanisms of aging processes under physiological 
conditions. Biogerontology 2005; 6: 283-290. 
24. Majno G, Joris I. Apoptosis, oncosis, and necrosis. An overview of cell death. Am 
J Pathol 1995; 146: 3-15. 
25. Haunstetter A, Izumo S. Apoptosis: basic mechanisms and implications for 
cardiovascular disease. Circ Res 1998; 82: 1111-1129. 
26. Andrews PA. Disorders of iron metabolism. N Engl J Med 2000; 342: 1293; 
author reply 1294. 
46 
 
27. Chen H, Liu B, Lukas TJ, Suyeoka G, Wu G, Neufeld AH. Changes in iron-
regulatory proteins in the aged rodent neural retina. Neurobiol Aging 2008. 
28. Finch CA, Deubelbeiss K, Cook JD, Eschbach JW, Harker LA, Funk DD, 
Marsaglia G, Hillman RS, Slichter S, Adamson JW, Ganzoni A, Biblett ER. Ferrokinetics 
in man. Medicine (Baltimore) 1970; 49: 17-53. 
29. Hershko C, Graham G, Bates GW, Rachmilewitz EA. Non-specific serum iron in 
thalassaemia: an abnormal serum iron fraction of potential toxicity. Br J Haematol 1978; 
40: 255-263. 
30. Porter JB, Abeysinghe RD, Marshall L, Hider RC, Singh S. Kinetics of removal 
and reappearance of non-transferrin-bound plasma iron with deferoxamine therapy. 
Blood 1996; 88: 705-713. 
31. Gutteridge JM, Rowley DA, Griffiths E, Halliwell B. Low-molecular-weight iron 
complexes and oxygen radical reactions in idiopathic haemochromatosis. Clin Sci 
(Lond) 1985; 68: 463-467. 
32. Eaton JW, Qian M. Molecular bases of cellular iron toxicity. Free Radic Biol Med 
2002; 32: 833-840. 
33. Esposito BP, Breuer W, Sirankapracha P, Pootrakul P, Hershko C, Cabantchik 
ZI. Labile plasma iron in iron overload: redox activity and susceptibility to chelation. 
Blood 2003; 102: 2670-2677. 
34. Templeton DM, Liu Y. Genetic regulation of cell function in response to iron 
overload or chelation. Biochim Biophys Acta 2003; 1619: 113-124. 
35. Andrews NC. Disorders of iron metabolism. N Engl J Med 1999; 341: 1986-1995. 
36. Hentze MW, Muckenthaler MU, Andrews NC. Balancing acts: molecular control 
of mammalian iron metabolism. Cell 2004; 117: 285-297. 
37. Wood JC, Enriquez C, Ghugre N, Otto-Duessel M, Aguilar M, Nelson MD, Moats 
R, Coates TD. Physiology and pathophysiology of iron cardiomyopathy in thalassemia. 
Ann N Y Acad Sci 2005; 1054: 386-395. 
38. Olivieri NF. The beta-thalassemias. N Engl J Med 1999; 341: 99-109. 
39. Olivieri NF, Nathan DG, MacMillan JH, Wayne AS, Liu PP, McGee A, Martin M, 
Koren G, Cohen AR. Survival in medically treated patients with homozygous beta-
thalassemia. N Engl J Med 1994; 331: 574-578. 
47 
 
40. Brittenham GM, Griffith PM, Nienhuis AW, McLaren CE, Young NS, Tucker EE, 
Allen CJ, Farrell DE, Harris JW. Efficacy of deferoxamine in preventing complications of 
iron overload in patients with thalassemia major. N Engl J Med 1994; 331: 567-573. 
41. Kohgo Y, Ikuta K, Ohtake T, Torimoto Y, Kato J. Body iron metabolism and 
pathophysiology of iron overload. Int J Hematol 2008; 88: 7-15. 
42. Vichinsky E. Clinical application of deferasirox: practical patient management. 
Am J Hematol 2008; 83: 398-402. 
43. Davis BA, O'Sullivan C, Jarritt PH, Porter JB. Value of sequential monitoring of 
left ventricular ejection fraction in the management of thalassemia major. Blood 2004; 
104: 263-269. 
44. Davis BA, Porter JB. Long-term outcome of continuous 24-hour deferoxamine 
infusion via indwelling intravenous catheters in high-risk beta-thalassemia. Blood 2000; 
95: 1229-1236. 
45. Lakatta E. Aging Effects on the Vasculature in Health: Risk Factors for 
Cardiovascular Disease. Am J Geriatr Cardiol 1994; 3: 11-17. 
46. Laurent S. Arterial wall hypertrophy and stiffness in essential hypertensive 
patients. Hypertension 1995; 26: 355-362. 
47. Muscari C, Giaccari A, Giordano E, Clo C, Guarnieri C, Caldarera CM. Role of 
reactive oxygen species in cardiovascular aging. Mol Cell Biochem 1996; 160-161: 159-
166. 
48. Harman D. The free radical theory of aging. Antioxid Redox Signal 2003; 5: 557-
561. 
49. Baskin SI, Kuhar KP, Uricchio FJ, Harper GR. The effect of age on five ions of 
the kidney in the Fischer 344 rat. Reprod Nutr Dev 1981; 21: 689-694. 
50. Killilea DW, Atamna H, Liao C, Ames BN. Iron accumulation during cellular 
senescence in human fibroblasts in vitro. Antioxid Redox Signal 2003; 5: 507-516. 
51. Killilea DW, Wong SL, Cahaya HS, Atamna H, Ames BN. Iron accumulation 
during cellular senescence. Ann N Y Acad Sci 2004; 1019: 365-367. 
52. Hahalis G, Alexopoulos D, Kremastinos DT, Zoumbos NC. Heart failure in beta-
thalassemia syndromes: a decade of progress. Am J Med 2005; 118: 957-967. 
53. Kalinowski DS, Richardson DR. The evolution of iron chelators for the treatment 
of iron overload disease and cancer. Pharmacol Rev 2005; 57: 547-583. 
48 
 
54. Richardson DR. Molecular mechanisms of iron uptake by cells and the use of 
iron chelators for the treatment of cancer. Curr Med Chem 2005; 12: 2711-2729. 
55. Asano S, Rice KM, Kakarla S, Katta A, Desai DH, Walker EM, Wehner P, Blough 
ER. Aging influences multiple indices of oxidative stress in the heart of the Fischer 
344/NNia x Brown Norway/BiNia rat. Redox Rep 2007; 12: 167-180. 
56. Rice KM, Preston DL, Walker EM, Blough ER. Aging influences multiple incidices 
of oxidative stress in the aortic media of the Fischer 344/NNiaxBrown Norway/BiNia rat. 
Free Radic Res 2006; 40: 185-197. 
57. Walker EM, Jr., Nillas MS, Mangiarua EI, Cansino S, Morrison RG, Perdue RR, 
Triest WE, Wright GL, Studeny M, Wehner P, Rice KM, Blough ER. Age-associated 
changes in hearts of male Fischer 344/Brown Norway F1 rats. Ann Clin Lab Sci 2006; 
36: 427-438. 
58. Wood JC, Otto-Duessel M, Gonzalez I, Aguilar MI, Shimada H, Nick H, Nelson 
M, Moats R. Deferasirox and deferiprone remove cardiac iron in the iron-overloaded 
gerbil. Transl Res 2006; 148: 272-280. 
59. Walker EM, Jr., Epling CP, Parris C, Cansino S, Ghosh P, Desai DH, Morrison 
RG, Wright GL, Wehner P, Mangiarua EI, Walker SM, Blough ER. Acetaminophen 
protects against iron-induced cardiac damage in gerbils. Ann Clin Lab Sci 2007; 37: 22-
33. 
60. Towbin H, Staehelin T, Gordon J. Electrophoretic transfer of proteins from 
polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc 
Natl Acad Sci U S A 1979; 76: 4350-4354. 
61. Hussein MR, Haemel AK, Wood GS. Apoptosis and melanoma: molecular 
mechanisms. J Pathol 2003; 199: 275-288. 
62. Puntarulo S. Iron, oxidative stress and human health. Mol Aspects Med 2005; 26: 
299-312. 
63. Kevin LG, Novalija E, Stowe DF. Reactive oxygen species as mediators of 
cardiac injury and protection: the relevance to anesthesia practice. Anesth Analg 2005; 
101: 1275-1287. 
64. Lipman RD. Pathobiology of aging rodents: inbred and hybrid models. Exp 
Gerontol 1997; 32: 215-228. 
65. Weindruch R. Animal models for use in aging research. J. Gerontol 1995; 50A: 
121-127. 
49 
 
66. Ahluwalia N, Lammi-Keefe CJ, Bendel RB, Morse EE, Beard JL, Haley NR. Iron 
deficiency and anemia of chronic disease in elderly women: a discriminant-analysis 
approach for differentiation. Am J Clin Nutr 1995; 61: 590-596. 
67. Holyoake TL, Stott DJ, McKay PJ, Hendry A, MacDonald JB, Lucie NP. Use of 
plasma ferritin concentration to diagnose iron deficiency in elderly patients. J Clin Pathol 
1993; 46: 857-860. 
68. Jung SH, DeRuisseau LR, Kavazis AN, DeRuisseau KC. Plantaris muscle of 
aged rats demonstrates iron accumulation and altered expression of iron regulation 
proteins. Exp Physiol 2008; 93: 407-414. 
69. Sullivan JL. The iron paradigm of ischemic heart disease. Am Heart J 1989; 117: 
1177-1188. 
70. Kakhlon O, Cabantchik ZI. The labile iron pool: characterization, measurement, 
and participation in cellular processes(1). Free Radic Biol Med 2002; 33: 1037-1046. 
71. Sherman AR, Helyar L, Wolinsky I. Effects of dietary protein concentration on 
trace minerals in rat tissues at different ages. J Nutr 1985; 115: 607-614. 
72. Dallman PR. Biochemical basis for the manifestations of iron deficiency. Annu 
Rev Nutr 1986; 6: 13-40. 
73. Roth JA, Horbinski C, Feng L, Dolan KG, Higgins D, Garrick MD. Differential 
localization of divalent metal transporter 1 with and without iron response element in rat 
PC12 and sympathetic neuronal cells. J Neurosci 2000; 20: 7595-7601. 
74. Ponka P, Beaumont C, Richardson DR. Function and regulation of transferrin 
and ferritin. Semin Hematol 1998; 35: 35-54. 
75. Halliwell B. The role of oxygen radicals in human disease, with particular 
reference to the vascular system. Haemostasis 1993; 23 Suppl 1: 118-126. 
76. Sprott RL. Development of animal models of aging at the National Institute of 
Aging. Neurobiol Aging 1991; 12: 635-638. 
77. Bernecker OY, Huq F, Heist EK, Podesser BK, Hajjar RJ. Apoptosis in heart 
failure and the senescent heart. Cardiovasc Toxicol 2003; 3: 183-190. 
78. Du J, Wang X, Miereles C, Bailey JL, Debigare R, Zheng B, Price SR, Mitch WE. 
Activation of caspase-3 is an initial step triggering accelerated muscle proteolysis in 
catabolic conditions. J Clin Invest 2004; 113: 115-123. 
50 
 
79. Phaneuf S, Leeuwenburgh C. Apoptosis and exercise. Med Sci Sports Exerc 
2001; 33: 393-396. 
80. Wahr PA, Michele DE, Metzger JM. Effects of aging on single cardiac myocyte 
function in Fischer 344 x Brown Norway rats. Am J Physiol Heart Circ Physiol 2000; 
279: H559-565. 
81. Higami Y, Shimokawa I. Apoptosis in the aging process. Cell Tissue Res 2000; 
301: 125-132. 
82. Gross A, Jockel J, Wei MC, Korsmeyer SJ. Enforced dimerization of BAX results 
in its translocation, mitochondrial dysfunction and apoptosis. Embo J 1998; 17: 3878-
3885. 
83. Oltvai ZN, Milliman CL, Korsmeyer SJ. Bcl-2 heterodimerizes in vivo with a 
conserved homolog, Bax, that accelerates programmed cell death. Cell 1993; 74: 609-
619. 
84. Hengartner MO. The biochemistry of apoptosis. Nature 2000; 407: 770-776. 
85. Szegezdi E, Fitzgerald U, Samali A. Caspase-12 and ER-stress-mediated 
apoptosis: the story so far. Ann N Y Acad Sci 2003; 1010: 186-194. 
 
 
 
 
 
 
 
51 
 
 
 
 
 
APPENDICES 
  
56 
 
Appendix A 
 
Table Legends 
 
Table 1. Effect of aging on heart weight and cardiac metal content and indices of 
liver and kidney function in 6-, 33-month control and 33-month treated F344BN 
rats.  
 
Table 2.  Tissue concentration of protein in hearts excised from young adult (6 
month), aged controls (33-month), and aged animals that had been treated with 
deferasirox for 6-months (33-month treated) F344BN rats.  Data was obtained from 
immunoblotting analysis.  Data are presented as percentages of the young adult value ± 
SE.  The results reflect the analysis of combined protein comparisons of four individual 
hearts from each age group.  An asterisk (*) designates significant differences from 6-
month age group (P < 0.05). 
 
Table 3. Effect of aging on indices of liver and kidney function in 6-, 33-month 
control and 33-month treated rats.  
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Table 1 
 
6month 
control 
33month 
control 
33month 
treated 
Physical 
characteristics 
 
 
 Body wt (g) 440  ±  24 512  ±  34* 472  ±  46 
Heart/body wt (%) 0.25 ± 0.01 0.37 ± 0.01* 0.41 ± 0.02* 
  
 
 Trace metals 
 
 
 Calcium 0.045 ± 0.006 0.096 ± 0.015* 0.073 ± 0.017 
Copper 2.872 ± 0.420 3.45 ± 0.558 3.616 ± 0.120 
Zinc 17.501 ± 4.558 17.145 ± 1.842 16.987 ± 0.273 
Magnesium 0.196 ± 0.011 0.231 ± 0.030 0.192 ± 0.022 
  
 
 An asterisk (*) indicates significant difference (P<0.05) from the 6-month control group. 
(n=6). 
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Table 2 
 
 
6month 
control  
33month 
control 
33month 
treated  
    Iron regulatory factors 
   Ferritin Heavy Chain 100 ± 2 94 ± 2* 90 ± 1* 
Ferritin Light Chain 100 ± 6 159 ± 16* 183 ± 13* 
Divalent  Metal Transporter-1 100 ±7 156 ± 14* 178 ± 16* 
Iron Regulatory Protein-1 100 ± 5 113 ± 4 103 ± 8 
Transferrin Receptor-1 100 ± 2 119 ± 5 111 ± 7 
    An asterisk (*) or cross (†) indicates significant difference (P<0.05) from 6-month control 
and sham chelation groups, respectively (n=6) 
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Table 3 
 
6month  
control 
33month      
control 
33month     
treated 
Blood parameters 
 
 
 ALB(g/dl) 3.2  ±  0.1 4  ±  0.2 3  ±  0.4 
ALP(u/l) 182  ±  13.7 169  ±  7.4 * 124  ±  9.9 *† 
ALT(u/l) 43  ±  4.4 90  ±  19.0 47  ±  7.2 
AMY(u/l) 750  ±  79.1 931  ±  134.1 715  ±  70.8 
BUN(mg/dl) 23  ±  1.1 17  ±  1.0 * 13  ±  1.2 * 
Ca+2(mg/dl) 11  ±  0.2 11  ±  0.2 11  ±  0.4 
CRE(mg/dl) 0.5  ±  0.1 0.3  ±  0.1 1.5  ±  0.9 
GLOB(g/dl) 2  ±  0.1 3  ±  0.2 * 3  ±  0.1 * 
K+(mmol/l) 8  ±  0.3 6  ±  0.1 6  ±  0.4 * 
Na+(mmol/l) 142  ±  2.4 149  ±  2.6 * 150  ±  1.7 * 
PHOS(mg/dl) 13  ±  1.2 8  ±  0.8 * 8  ±  0.2 * 
TBIL(mg/dl) 0.3  ±  0.03 0.4  ±  0.01 0.4  ±  0.03 
TP(g/dl) 6  ±  0.2 7  ±  0.4 6  ±  0.4 
 
An asterisk (*) or cross (†) indicates significant difference (P<0.05) from age matched 
control and sham chelation groups, respectively (n=6) 
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Figure Legends 
 
Figure 1. Deferasirox treatment prevents age-associated increases in cardiac 
iron.  Tissue iron levels of rats in the experimental groups as determined by ICP-AES 
measurements.  (*) indicates significant difference from 6-month control animals 
(P<0.05), (†) indicates significant difference from 33-month control animals (P<0.05). 
 
Figure 2. Aged hearts exhibit increases in the amount of ferritin light chain and 
divalent metal transporter-1.  Protein content as determined by Western blot analysis.  
 
Figure 3. Deferasirox treatment attenuates age-associated increases in cardiac 
apoptosis. Representative cross-sections showing nuclei exhibiting DNA strand 
breakage as determined by the TUNEL staining in 6-month, 33-month control and 33-
month treated animals. 
 
Figure  4. Bax / Bcl2 content is increased with age.  Protein content was determined 
by performing Western blot analysis.  Data are presented as means ± SE. * significantly 
different from 6-month values (P<0.05).  † Significantly different from 33-month control 
values (P<0.05).  
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Figure 5. Bad protein levels are higher with age and decreased by deferasirox 
treatment. Protein content was determined by performing Western blot analysis. Data 
are presented as means ± SE.  *Significantly different from 6-month values (P<0.05).  † 
Significantly different from 33-month control values (P<0.05).  
 
Figure 6. Deferasirox treatment decreases the amount of activated caspase-12.  
Protein content was determined by performing Western blot analysis.  Data are 
presented as means ± SE.  * Significantly different from 6-month values (P<0.05).  † 
Significantly different from 33-month control values (P<0.05).  
 
 
62 
 
Figure 1. Deferasirox treatment prevents age-associated increases in cardiac iron 
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Figure 2. Aged hearts exhibit increases in the amount of ferritin light chain and 
divalent metal transporter-1 
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Figure 3. Deferasirox treatment attenuates age-associated increases in cardiac 
apoptosis 
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Figure 4. Bax / Bcl2 content is increased with age 
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Figure 5. Bad protein levels are higher in aged rats and decreased by deferasirox 
treatment 
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Figure 6. Deferasirox treatment decreases the amount of activated caspase-12 
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AppendixB 
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Raw data 
 This section represents the raw data tables produced from spot densitometry of the  
  immunoblot films 
 
 
 
 
 
 
 
 
 
 
 
 
6m CON 33m CON 33m TRT
%C 33.70 34.70 31.70
%C 37.40 32.20 30.40
%C 36.30 33.70 30.00
N 3 3 3
Mean 35.80 33.53 30.70
Strandard Deviation 1.90 1.26 0.89
Standard Error of the mean 1.34 0.89 0.63
6m CON 33m CON 33m TRT
Relative Expression Level 1.00 0.94 0.86
Standard error of the mean 0.04 0.02 0.02
6m CON 33m CON 33m TRT
% RE 100 93.668529 85.75419
SE 3.752801353 2.4853534 1.7555594
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One Way Analysis of Variance 
 
Data source: Data 1 in Notebook 1 
 
Normality Test: Passed (P = 0.786) 
 
Equal Variance Test: Passed (P = 0.488) 
 
Group Name  N  Missing Mean Std Dev SEM  
6 Cont 3 0 35.800 1.900 1.097  
33m Cont 3 0 33.533 1.258 0.726  
33 m Trt 3 0 30.700 0.889 0.513  
 
Source of Variation DF   SS   MS    F    P   
Between Groups 2 39.176 19.588 9.821 0.013  
Residual 6 11.967 1.994    
Total 8 51.142     
 
The differences in the mean values among the treatment groups are greater than would 
be expected by chance; there is a statistically significant difference  (P = 0.013). 
 
Power of performed test with alpha = 0.050: 0.828 
 
 
All Pairwise Multiple Comparison Procedures (Student-Newman-Keuls Method) : 
 
Comparisons for factor:  
Comparison Diff of Means p q P P<0.050  
6 Cont vs. 33 m Trt 5.100 3 6.255 0.011 Yes  
6 Cont vs. 33m Cont 2.267 2 2.780 0.097 No  
33m Cont vs. 33 m Trt 2.833 2 3.475 0.049 Yes  
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Raw data 
 This section represents the raw data tables produced from spot densitometry of the  
  Immunoblot films 
 
 
 
 
 
 
 
 
 
 
 
6m CON 33m CON 33 m TRT
%C 26.30 37.10 36.60
%C 20.30 41.70 38.00
%C 24.40 45.50 30.10
N 3.00 3.00 3.00
Mean 23.66666667 41.433333 34.9
Strandard Deviation 3.07 4.21 4.22
Standard Error of the mean 2.17 2.97 2.98
6m CON 33m CON 33m TRT
Relative Expression Level 1 1.7507042 1.4746479
Standard error of the mean 0.09 0.13 0.13
6m CON 33m CON 33m TRT
% RE 100 175.07042 147.46479
SE 9.161969125 12.567611 12.59481
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One Way Analysis of Variance 
 
Data source: Data 1 in Notebook 2 
 
Normality Test: Passed (P = 0.391) 
 
Equal Variance Test: Passed (P = 0.865) 
 
Group Name  N  Missing Mean Std Dev SEM  
6m CON 3 0 23.667 3.066 1.770  
33m CON 3 0 41.433 4.206 2.429  
33 m TRT 3 0 34.900 4.215 2.434  
 
Source of Variation DF   SS   MS    F    P   
Between Groups 2 484.527 242.263 16.199 0.004  
Residual 6 89.733 14.956    
Total 8 574.260     
 
The differences in the mean values among the treatment groups are greater than would 
be expected by chance; there is a statistically significant difference (P = 0.004). 
 
Power of performed test with alpha = 0.050: 0.970 
 
 
All Pairwise Multiple Comparison Procedures (Student-Newman-Keuls Method): 
 
Comparisons for factor:  
Comparison Diff of Means p q P P<0.050  
33m CON vs. 6m CON 17.767 3 7.957 0.003 Yes  
33m CON vs. 33 m TRT 6.533 2 2.926 0.084 No  
33 m TRT vs. 6m CON 11.233 2 5.031 0.012 Yes  
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Raw data 
 This section represents the raw data tables produced from spot densitometry of the  
  immunoblot films 
 
 
 
 
 
 
 
 
 
 
6m CON 33m CON 33m TRT
%C 42.9 40.3 16.9
%C 29.90 44.80 25.30
%C 29.70 45.90 24.30
N 3 3 3
Mean 34.16666667 43.666667 22.166667
Strandard Deviation 7.56 2.97 4.59
Standard Error of the mean 5.35 2.10 3.24
6m CON 33m CON 33m TRT
Relative Expression Level 1 1.2780488 0.6487805
Standard error of the mean 0.15654205 0.0614053 0.0949605
6 CON 33m CON 33m TRT
% RE 100 127.80488 64.878049
SE 15.65420501 6.1405315 9.4960463
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One Way Analysis of Variance 
 
Data source: Data 1 in Notebook 3 
 
Normality Test: Passed (P = 0.501) 
 
Equal Variance Test: Passed (P = 0.825) 
 
Group Name  N  Missing Mean Std Dev SEM  
6 Cont 3 0 34.167 7.564 4.367  
33m Cont 3 0 43.667 2.967 1.713  
33 m Trt 3 0 22.167 4.588 2.649  
 
Source of Variation DF   SS   MS    F    P   
Between Groups 2 696.500 348.250 11.999 0.008  
Residual 6 174.140 29.023    
Total 8 870.640     
 
The differences in the mean values among the treatment groups are greater than would 
be expected by chance; there is a statistically significant difference  (P = 0.008). 
 
Power of performed test with alpha = 0.050: 0.903 
 
 
All Pairwise Multiple Comparison Procedures (Student-Newman-Keuls Method) : 
 
Comparisons for factor:  
Comparison Diff of Means p q P P<0.050  
33m Cont vs. 33 m Trt 21.500 3 6.912 0.007 Yes  
33m Cont vs. 6 Cont 9.500 2 3.054 0.074 No  
6 Cont vs. 33 m Trt 12.000 2 3.858 0.034 Yes  
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Raw data 
 This section represents the raw data tables produced from spot densitometry of the  
  immunoblot films 
 
 
 
 
 
 
 
 
 
 
 
6m CON 33m CON 33m TRT
%C 40.00 32.70 27.30
%C 26.10 37.00 37.00
%C 23.30 34.90 41.90
N 3 3 3
Mean 32.35 34.33 33.38
Strandard Deviation 16.40 15.45 16.21
Standard Error of the mean 11.59 10.93 11.46
6m CON 33m CON 33m TRT
Relative Expression Level 1.00 1.06 1.03
Standard error of the mean 0.36 0.34 0.35
6m CON 33m CON 33m TRT
% RE 100 106.1051 103.16847
SE 35.83694698 33.779863 35.426509
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One Way Analysis of Variance  
 
Data source: Data 1 in Notebook 4 
 
Normality Test: Passed (P = 0.660) 
 
Equal Variance Test: Passed (P = 0.493) 
 
Group Name  N  Missing Mean Std Dev SEM  
6 Cont 3 0 29.800 8.944 5.164  
33m Cont 3 0 34.867 2.150 1.241  
33 m Trt 3 0 35.400 7.430 4.290  
 
Source of Variation DF   SS   MS    F    P   
Between Groups 2 57.316 28.658 0.615 0.572  
Residual 6 279.647 46.608    
Total 8 336.962     
 
The differences in the mean values among the treatment groups are not great enough 
to exclude the possibility that the difference is due to random sampling variability; there 
is not a statistically significant difference  (P = 0.572). 
 
Power of performed test with alpha = 0.050: 0.050 
 
The power of the performed test (0.050) is below the desired power of 0.800. 
Less than desired power indicates you are less likely to detect a difference when one 
actually exists. Negative results should be interpreted cautiously. 
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Raw data 
 This section represents the raw data tables produced from spot densitometry of the  
  immunoblot films 
 
 
 
 
 
 
 
 
 
6m CON 33m CON 33m TRT
%C 41.80 32.00 26.30
%C 36.80 35.60 27.60
%C 34.50 35.10 30.40
N 3.00 3.00 3.00
Mean 38.725 33.675 27.65
Strandard Deviation 17.61 15.15 12.48
Standard Error of the mean 12.45 10.72 8.82
6m CON 33m CON 33m TRT
Relative Expression Level 1 0.8695933 0.714009
Standard error of the mean 0.32 0.28 0.23
6m CON 33m CON 33m TRT
% RE 100 86.959329 71.400904
SE 32.15169258 27.670401 22.784927
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One Way Analysis of Variance 
 
Data source: Data 1 in Notebook 5 
 
Normality Test: Passed (P = 0.786) 
 
Equal Variance Test: Passed (P = 0.547) 
 
Group Name  N  Missing Mean Std Dev SEM  
6 Cont 3 0 37.700 3.732 2.155  
33m Cont 3 0 34.233 1.950 1.126  
33 m Trt 3 0 28.100 2.095 1.210  
 
Source of Variation DF   SS   MS    F    P   
Between Groups 2 141.796 70.898 9.614 0.013  
Residual 6 44.247 7.374    
Total 8 186.042     
 
The differences in the mean values among the treatment groups are greater than would 
be expected by chance; there is a statistically significant difference (P = 0.013). 
 
Power of performed test with alpha = 0.050: 0.819 
 
 
All Pairwise Multiple Comparison Procedures (Student-Newman-Keuls Method): 
 
Comparisons for factor:  
Comparison Diff of Means p q P P<0.050  
6 CON vs. 33 m TRT 9.600 3 6.123 0.012 Yes  
6 CON vs. 33m CON 3.467 2 2.211 0.169 No  
33m CON vs. 33 m TRT 6.133 2 3.912 0.033 Yes  
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 Raw data 
 This section represents the raw data tables produced from spot densitometry of the  
  immunoblot films 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
6m CON 33m CON 33m TRT
%C 26.8 34.5 38.7
%C 25.7 36.2 38.1
%C 24.9 33.5 41.6
N 3 3 3
Mean 25.80 34.73 39.47
Strandard Deviation 0.95 1.37 1.87
Standard Error of the mean 0.67 0.97 1.32
6 m CON 33m CON 33 m TRT
Relative Expression Level 1.00 1.3463 1.53
Standard error of the mean 0.03 0.04 0.05
6m CON 33m CON 33m TRT
% RE 100.00 134.63 152.97
SE 2.61 3.74 5.13
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One Way Analysis of Variance 
 
Data source: Data 1 in Notebook 6 
 
Normality Test: Passed (P = 0.390) 
 
Equal Variance Test: Passed (P = 0.744) 
 
Group Name  N  Missing Mean Std Dev SEM  
6 Cont 3 0 25.800 0.954 0.551  
33m Cont 3 0 34.733 1.365 0.788  
33 m Trt 3 0 39.467 1.872 1.081  
 
Source of Variation DF   SS   MS    F    P   
Between Groups 2 288.987 144.493 69.062 <0.001 
Residual 6 12.553 2.092    
Total 8 301.540     
 
The differences in the mean values among the treatment groups are greater than would 
be expected by chance; there is a statistically significant difference (P = <0.001). 
 
Power of performed test with alpha = 0.050: 1.000 
 
 
All Pairwise Multiple Comparison Procedures (Student-Newman-Keuls Method): 
 
Comparisons for factor:  
Comparison Diff of Means p q P P<0.050  
33 m Trt vs. 6 Cont 13.667 3 16.365 <0.001 Yes  
33 m Trt vs. 33m Cont 4.733 2 5.668 0.007 Yes  
33m Cont vs. 6 Cont 8.933 2 10.697 <0.001 Yes  
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Raw data 
 This section represents the raw data tables produced from spot densitometry of the  
  immunoblot films 
  
 
 
 
 
 
 
 
 
 
6m CON 33m CON 33 m TRT
%C 24 42.8 33.2
%C 17.7 47.4 34.9
%C 11 47.6 41.5
N 3 3 3
Mean 17.57 45.93 36.53
Strandard Deviation 6.50 2.72 4.38
Standard Error of the mean 4.60 1.92 3.10
6m CON 33m CON 33m TRT
Relative Expression Level 1.00 2.6148 2.08
Standard error of the mean 0.26 0.11 0.18
6m CON 33m CON 33m TRT
% RE 100.00 261.48 207.97
SE 26.17 10.93 17.65
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One Way Analysis of Variance 
 
Data source: Data 1 in Notebook 7 
 
Normality Test: Passed (P = 0.734) 
 
Equal Variance Test: Passed (P = 0.422) 
 
Group Name  N  Missing Mean Std Dev SEM  
6m Cont 3 0 17.567 6.501 3.753  
33m Cont 3 0 45.933 2.715 1.568  
33 m Trt 3 0 36.533 4.384 2.531  
 
Source of Variation DF   SS   MS    F    P   
Between Groups 2 1252.762 626.381 27.289 <0.001  
Residual 6 137.720 22.953    
Total 8 1390.482     
 
The differences in the mean values among the treatment groups are greater than would 
be expected by chance; there is a statistically significant difference  (P = <0.001). 
 
Power of performed test with alpha = 0.050: 0.999 
 
 
All Pairwise Multiple Comparison Procedures (Student-Newman-Keuls Method) : 
 
Comparisons for factor:  
Comparison Diff of Means p q P P<0.050  
33m Cont vs. 6m Cont 28.367 3 10.255 0.001 Yes  
33m Cont vs. 33 m Trt 9.400 2 3.398 0.053 No  
33 m Trt vs. 6m Cont 18.967 2 6.857 0.003 Yes  
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  Raw data 
 This section represents the raw data tables produced from spot densitometry of the  
  immunoblot films 
Ferritin light chain 6m CON 33m CON 33 m TRT 
 
36 32 32 
 
36 32 32 
 
34 35 31 
panceau stain 6m CON 33m CON 33 m TRT 
 
35 32 33 
 
33 34 33 
 
33 35 32 
Ratio 6m CON 33m CON 33 m TRT 
 
1.04 1.00 0.95 
 
1.10 0.96 0.95 
 
1.03 1.01 0.96 
    N 3.00 3.00 3.00 
Mean 1.06 0.99 0.95 
STDEV 0.04 0.03 
 
0.01 
 
SEM 0.03 0.02 0.01 
    
 
6m CON 33m CON 33m TRT 
Relative expression 1.00 0.94 0.90 
Standard error of the 
mean         0.03 
                  
0.02 0.01 
    
 
6m CON 33m CON 33m TRT 
% RE 100.00 93.64 90.11 
SE 2.57 1.87 0.61 
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One Way Analysis of Variance 
 
Data source: Data 1 in Notebook 1 
 
Normality Test: Passed (P = 0.770) 
 
Equal Variance Test: Passed (P = 0.496) 
 
Group Name  N  Missing Mean Std Dev SEM  
6m CON 3 0 1.057 0.0384 0.0222  
33m CON 3 0 0.990 0.0279 0.0161  
33 m TRT 3 0 0.953 0.00906 0.00523  
 
Source of Variation DF   SS   MS    F    P   
Between Groups 2 0.0169 0.00843 10.815 0.010 
Residual 6 0.00467 0.000779    
Total 8 0.0215     
 
The differences in the mean values among the treatment groups are greater than would 
be expected by chance; there is a statistically significant difference (P = 0.010). 
 
Power of performed test with alpha = 0.050: 0.867 
 
 
All Pairwise Multiple Comparison Procedures (Student-Newman-Keuls Method): 
 
Comparisons for factor:  
Comparison Diff of Means p q P P<0.050  
6m CON vs. 33 m TRT 0.105 3 6.490 0.009 Yes  
6m CON vs. 33m CON 0.0672 2 4.171 0.026 Yes  
33m CON vs. 33 m TRT0.0374 2 2.318 0.152 No  
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Raw data 
 This section represents the raw data tables produced from spot densitometry of the  
  immunoblot films 
Ferritin light chain 6m CON 33m CON 33 m TRT 
 
23.3 40 36.7 
 
20.6 35.1 44.3 
 
24.5 33 42.6 
    panceau stain 6m CON 33m CON 33 m TRT 
 
34.5 31 33.2 
 
32.8 33.7 33.4 
 
32.7 34.8 32.4 
    Ratio 6m CON 33m CON 33 m TRT 
 
0.675362 1.2903226 1.1054217 
 
0.628049 1.041543 1.3263473 
 
0.749235 0.9482759 1.3148148 
    N 3 3 3 
Mean 0.684216 1.0933805 1.2488613 
STDEV 0.061076 0.1768172 
 
0.1243561 
 
SEM 0.043188 0.1250287 0.087933 
    
 
6m CON 33m CON 33 m TRT 
Relative expression 1 1.598006 1.8252454 
Standard error of the 
mean 0.06 0.18 0.13 
    
 
6m CON 33m CON 33m TRT 
% RE 100 159.8006 182.52454 
SE 6.311988 18.273286 12.851656 
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One Way Analysis of Variance 
 
Data source: Data 1 in Notebook 1 
 
Normality Test: Passed (P = 0.602) 
 
Equal Variance Test: Passed (P = 0.615) 
 
Group Name  N  Missing Mean Std Dev SEM  
6m CON 3 0 0.684 0.0611 0.0353  
33m CON 3 0 1.093 0.177 0.102  
33 m TRT 3 0 1.249 0.124 0.0718  
 
Source of Variation DF   SS   MS    F    P   
Between Groups 2 0.510 0.255 15.173 0.004  
Residual 6 0.101 0.0168    
Total 8 0.611     
 
The differences in the mean values among the treatment groups are greater than would 
be expected by chance; there is a statistically significant difference  (P = 0.004). 
 
Power of performed test with alpha = 0.050: 0.960 
 
 
All Pairwise Multiple Comparison Procedures (Student-Newman-Keuls Method): 
 
Comparisons for factor:  
Comparison Diff of Means p q P P<0.050  
33 m TRT vs. 6m CON 0.565 3 7.541 0.004 Yes  
33 m TRT vs. 33m CON0.155 2 2.076 0.193 No  
33m CON vs. 6m CON 0.409 2 5.464 0.009 Yes  
 
 
 
 
94 
 
 
 
95 
 
Raw data 
 This section represents the raw data tables produced from spot densitometry of the  
  immunoblot films 
 
DMT1 6m CON 33m CON 33 m TRT 
 
23 40 37 
 
21 35 44 
 
25 33 43 
    ponceau stain 6m CON 33m CON 33 m TRT 
 
32.8 32 35.2 
 
33.3 34.2 32.5 
 
33 33.9 33 
    Ratio 6m CON 33m CON 33 m TRT 
 
0.70122 1.25 1.0511364 
 
0.630631 1.0233918 1.3538462 
 
0.757576 0.9734513 1.3030303 
    N 3 3 3 
Mean 0.696475 1.082281 1.2360043 
STDEV 0.063605 0.1473796 
 
0.1621039 
 
SEM 0.044976 0.1042131 0.1146248 
    
 
6m CON 33m CON 33 m TRT 
Relative expression 1 1.5539403 
 
1.7746563 
 
Standard error of the 
mean 0.06 0.15 0.16 
    
 
6m CON 33m CON 33m TRT 
% RE 100 155.39403 177.46563 
SE 6.457632 14.962931 16.457835 
 
 
96 
 
One Way Analysis of Variance 
  
Data source: Data 1 in Notebook 1 
 
Normality Test: Passed (P = 0.800) 
 
Equal Variance Test: Passed (P = 0.715) 
 
Group Name  N  Missing Mean Std Dev SEM  
6m CON 3 0 0.696 0.0636 0.0367  
33m CON 3 0 1.082 0.147 0.0851  
33 m TRT 3 0 1.236 0.162 0.0936  
 
Source of Variation DF   SS   MS    F    P   
Between Groups 2 0.464 0.232 13.361 0.006  
Residual 6 0.104 0.0173    
Total 8 0.568     
 
The differences in the mean values among the treatment groups are greater than would 
be expected by chance; there is a statistically significant difference (P = 0.006). 
 
Power of performed test with alpha = 0.050: 0.933 
 
 
All Pairwise Multiple Comparison Procedures (Student-Newman-Keuls Method): 
 
Comparisons for factor:  
Comparison Diff of Means p q P P<0.050  
33 m TRT vs. 6m CON 0.540 3 7.095 0.006 Yes  
33 m TRT vs. 33m CON0.154 2 2.022 0.203 No  
33m CON vs. 6m CON 0.386 2 5.073 0.012 Yes  
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Raw data 
 This section represents the raw data tables produced from spot densitometry of the  
  immunoblot films 
IRP1 6m CON 33m CON 33 m TRT 
 
29.4 34 36.6 
 
31.1 35.3 33.6 
 
33.6 38.2 28.1 
    ponceau stain 6m CON 33m CON 33 m TRT 
 
32.8 32 35.2 
 
33.3 34.2 32.5 
 
33 33.9 33 
    Ratio 6m CON 33m CON 33 m TRT 
 
0.896341 1.0625 1.0397727 
 
0.933934 1.0321637 1.0338462 
 
1.018182 1.1268437 0.8515152 
    N 3 3 3 
Mean 0.949486 1.0738358 0.9750447 
STDEV 0.062391 0.0483471 0.1070207 
SEM 0.044117 0.0341866 0.0756751 
    
 
6m CON 33m CON 33 m TRT 
Relative expression 1 1.1309657 1.0269187 
Standard error of the 
mean 0.046464 0.0360054 
 
0.0797011 
 
    
 
6m CON 33m CON 33m TRT 
% RE 100 113.09657 102.69187 
SE 4.646435 3.6005383 7.9701135 
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One Way Analysis of Variance 
  
Data source: Data 1 in Notebook 1 
 
Normality Test: Passed (P = 0.355) 
 
Equal Variance Test: Passed (P = 0.828) 
 
Group Name  N  Missing Mean Std Dev SEM  
6m CON 3 0 0.949 0.0624 0.0360  
33m CON 3 0 1.074 0.0483 0.0279  
33 m TRT 3 0 0.975 0.107 0.0618  
 
Source of Variation DF   SS   MS    F    P   
Between Groups 2 0.0259 0.0129 2.195 0.193  
Residual 6 0.0354 0.00589    
Total 8 0.0612     
 
The differences in the mean values among the treatment groups are not great enough 
to exclude the possibility that the difference is due to random sampling variability; there 
is not a statistically significant difference  (P = 0.193). 
 
Power of performed test with alpha = 0.050: 0.173 
 
The power of the performed test (0.173) is below the desired power of 0.800. 
Less than desired power indicates you are less likely to detect a difference when one 
actually exists. Negative results should be interpreted cautiously. 
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Raw data 
 This section represents the raw data tables produced from spot densitometry of the  
  immunoblot films 
 
TfR1 6m CON 33m CON 33 m TRT 
 
31.9 33.8 34.3 
 
33.00 33.00 34.00 
 
33.9 31.7 34.4 
    ponceau stain 6m CON 33m CON 33 m TRT 
 
33.9 33.3 32.7 
 
32.8 33.7 33.4 
 
34 33.7 32.2 
    Ratio 6m CON 33m CON 33 m TRT 
 
0.941003 1.015015 1.0489297 
 
1.006098 0.9792285 1.0179641 
 
0.997059 0.9406528 1.068323 
    N 3 3 3 
Mean 0.981386 0.9782988 1.0450722 
STDEV 0.035264 0.0371898 0.0254001 
SEM 0.024935 0.0262972 0.0179606 
    
 
6m CON 33m CON 33 m TRT 
Relative expression 1 0.9968538 1.0648937 
Standard error of the 
mean 0.025408 0.0267959 0.0183012 
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One Way Analysis of Variance 
 
Data source: Data 1 in Notebook 1 
 
Normality Test: Passed (P = 0.505) 
 
Equal Variance Test: Passed (P = 0.839) 
 
Group Name  N  Missing Mean Std Dev SEM  
6m CON 3 0 0.981 0.0353 0.0204  
33m CON 3 0 0.978 0.0372 0.0215  
33 m TRT 3 0 1.045 0.0254 0.0147  
 
Source of Variation DF   SS   MS    F    P   
Between Groups 2 0.00852 0.00426 3.908 0.082  
Residual 6 0.00654 0.00109    
Total 8 0.0151     
 
The differences in the mean values among the treatment groups are not great enough 
to exclude the possibility that the difference is due to random sampling variability; there 
is not a statistically significant difference  (P = 0.082). 
 
Power of performed test with alpha = 0.050: 0.366 
 
The power of the performed test (0.366) is below the desired power of 0.800. 
Less than desired power indicates you are less likely to detect a difference when one 
actually exists. Negative results should be interpreted cautiously. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
